Evidence map›Paper›PMID 40493293›Full record

Trial reportJournal of neuro-oncology2025

Whole Body-MRI assessment of peripheral lesions in patients with NF2-related schwannomatosis on systemic bevacizumab.

Shivani Ahlawat, Patrick Debs, Laura M Fayad, Scott R Plotkin, Brigitte C Widemann, Jaishri O Blakeley

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shivani AhlawatThe Russel H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Johns Hopkins Medical Institutions, 601 North Caroline Street, 3rd Floor, Baltimore, MD, 21287, USA. sahlawa1@jhmi.edu.
Patrick DebsThe Russel H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Johns Hopkins Medical Institutions, 601 North Caroline Street, 3rd Floor, Baltimore, MD, 21287, USA.
Laura M FayadThe Russel H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Johns Hopkins Medical Institutions, 601 North Caroline Street, 3rd Floor, Baltimore, MD, 21287, USA.
Scott R PlotkinCancer Center, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Brigitte C WidemannPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Jaishri O BlakeleyDepartment of Neurology, Neuro-Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe the whole-body magnetic resonance (WB-MRI) features of peripheral schwannomas in patients with NF2-related schwannomatosis (SWN) treated with bevacizumab for target progressive/symptomatic vestibular schwannomas (VSs).

methodsIn this multi-institution, open-label phase II clinical trial, WB-MRI at 3.0T was performed at baseline, 25-weeks, and 49-weeks after treatment with bevacizumab using STIR, DWI/ADC mapping, pre- and post-contrast T1-weighted imaging. Two readers recorded size and signal characteristics of non-target peripheral lesions (maximum 5 lesions per patient (each from a different body region)). 2D-area (product of two perpendicular measurements), inter-reader reliability and percent change (baseline-49 weeks) was calculated. Radiological response was defined as complete response (CR, disappearance), partial response (PR, > 20% decrease), progressive disease (PD, > 20% increase), and stable disease (SD).

resultsBaseline WB-MRI detected 119 non-target peripheral schwannomas (median:8; range:0-37). Thirty-three peripheral schwannomas in 11 patients (median age (years): 30(range:14-79)) were characterized. Median size(mm) at baseline, 25-weeks, and 49-weeks was 26 (range: 10-88), 26 (range: 10-86), and 25 (range: 9-86), respectively. Lesions were measured with high inter-reader reliability (ICC range 0.990-0.997). Based on largest lesion diameter, all non-target lesions were stable at 49-weeks. Based on 2D-area, the majority of the lesions were SD (31/33 (94%) followed by PR (1/33;3%) and PD (1/33; 3%). There was no change in ADC values or other signal characteristics at 49-weeks.

conclusionsIn NF2-related SWN, WB-MRI enables detection and characterization of peripheral non-target schwannomas as small as 10 mm with high-inter reader reliability. Despite histological similarities to central VSs (targeted for progression), non-target peripheral schwannomas predominantly remained stable on bevacizumab.

Indexed as

Antineoplastic Agents, ImmunologicalBevacizumabNeurilemmomaNeurofibromatosesNeurofibromatosis 2Skin NeoplasmsWhole Body ImagingAdultAgedFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMaleMiddle AgedYoung AdultAntineoplastic Agents, ImmunologicalBevacizumabBevacizumab, whole body MRIDiffusion weighted imagingNeurofibromatosis type 2NF2-related schwannomatosisSchwannoma

Identifiers

PMID40493293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.